Ensysce Biosciences, Inc (ENSC): Price and Financial Metrics


Ensysce Biosciences, Inc (ENSC): $0.70

-0.01 (-1.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENSC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENSC Stock Price Chart Interactive Chart >

Price chart for ENSC

ENSC Price/Volume Stats

Current price $0.70 52-week high $36.47
Prev. close $0.71 52-week low $0.59
Day low $0.66 Volume 1,110,307
Day high $0.73 Avg. volume 4,723,840
50-day MA $1.27 Dividend yield N/A
200-day MA $7.53 Market Cap 4.49M

Ensysce Biosciences, Inc (ENSC) Company Bio


Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.


ENSC Latest News Stream


Event/Time News Detail
Loading, please wait...

ENSC Latest Social Stream


Loading social stream, please wait...

View Full ENSC Social Stream

Latest ENSC News From Around the Web

Below are the latest news stories about ENSYSCE BIOSCIENCES INC that investors may wish to consider to help them evaluate ENSC as an investment opportunity.

Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the initiation of the final stage of the Phase 1 study of PF614-MPAR.

Yahoo | January 25, 2023

Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on Wednesday, January 25th, 2023, at 12:20 p.m. Eastern Time.

Yahoo | January 23, 2023

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on January 25, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-m

Yahoo | January 23, 2023

Ensysce Biosciences Issues 2023 Shareholder Letter

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.

Yahoo | January 11, 2023

Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has successfully completed the clinical portion of study PF614-104, ‘A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone

Yahoo | January 4, 2023

Read More 'ENSC' Stories Here

ENSC Price Returns

1-mo -6.67%
3-mo -75.35%
6-mo -92.63%
1-year -97.99%
3-year N/A
5-year N/A
YTD -6.67%
2022 -99.20%
2021 -62.20%
2020 19.33%
2019 6.11%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5571 seconds.